Cyclic Peptide Screening Methods for Preclinical Drug Discovery

J Med Chem. 2022 Sep 22;65(18):11913-11926. doi: 10.1021/acs.jmedchem.2c01077. Epub 2022 Sep 8.

Abstract

Cyclic peptides are among the most diverse architectures for current drug discovery efforts. Their size, stability, and ease of synthesis provide attractive scaffolds to engage and modulate some of the most challenging targets, including protein-protein interactions and those considered to be "undruggable". With a variety of sophisticated screening technologies to produce libraries of cyclic peptides, including phage display, mRNA display, split intein circular ligation of peptides, and in silico screening, a new era of cyclic peptide drug discovery is at the forefront of modern medicine. In this perspective, we begin by discussing cyclic peptides approved for clinical use in the past two decades. Particular focus is placed around synthetic chemistries to generate de novo libraries of cyclic peptides and novel methods to screen them. The perspective culminates with future prospects for generating cyclic peptides as viable therapeutic options and discusses the advantages and disadvantages currently being faced with bringing them to market.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Discovery / methods
  • Peptide Library*
  • Peptides, Cyclic* / genetics
  • Peptides, Cyclic* / pharmacology
  • RNA, Messenger

Substances

  • Peptide Library
  • Peptides, Cyclic
  • RNA, Messenger